PeptidePedia The community reference

Talk:Adverse effects of GLP-1 receptor agonists

Discussion page·2 threads·no archives

This article is within the scope of the clinical practice working group.

This is the discussion page for the article Adverse effects of GLP-1 receptor agonists. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Placebo-arm nauseaResolved

Raw active-arm frequencies overstate the attributable excess because placebo-arm nausea is 10 to 20% in the same trials. That belongs next to the table. — NauseaNoor (talk) 09:45, 6 February 2026 (UTC)

Added immediately after it, with the link to Placebo-adjusted effect for the general principle. ✓ Done — ForestPlotFinn (talk) 13:20, 6 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Precautionary contraindicationDone

Describing the thyroid contraindication as precautionary, with the rodent receptor-density difference given as the reason no human signal is expected, is accurate and neither alarming nor dismissive. — MTC_Marisol (talk) 10:30, 13 April 2026 (UTC)

And it says no human signal has been established rather than that none exists. ✓ Done — HedgeHedda (talk) 14:05, 13 April 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.
This page was last edited on 13 April 2026, by HedgeHedda. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).